Lantus (insulin glargine) is a prescription drug that’s used to manage blood sugar levels in people with diabetes. Lantus’s cost may depend on your dosage, whether you have health insurance, and the ...
March 16 (Reuters) - Sanofi SA (SASY.PA), opens new tab said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...
The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...
Initiators of biosimilar insulin glargine-yfgn were more likely to reside in rural areas, live in long-term care facilities, or have multiple prescribers and were less likely to have previously used ...
LONDON (Reuters) - A once-daily injection of Sanofi-Aventis's insulin drug Lantus controls blood sugar as effectively as Eli Lilly's Humalog, which needs to be taken three times daily, researchers ...
Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Semglee ...
(Reuters) -Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results